Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann N Y Acad Sci. 2011 Oct;1236:30-43. doi: 10.1111/j.1749-6632.2011.06216.x.

Advancing drug discovery for schizophrenia.

Author information

1
Semel Institute for Neuroscience at the University of California, Los Angeles, California, USA.

Erratum in

  • Ann N Y Acad Sci. 2012 Jul;1259:145. Saw, Akira [corrected to Sawa, Akira].

Abstract

Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, "Advancing Drug Discovery for Schizophrenia" was held March 9-11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.

PMID:
22032400
PMCID:
PMC3787879
DOI:
10.1111/j.1749-6632.2011.06216.x
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center